Biotech stocks are emerging from a four-year slump. The SPDR S&P Biotech exchange-traded fund XBI, a proxy for the sector, is up 25% so far this year through Oct. 31, beating the S&P 500 SPX by 9 ...
After years of disappointments, biotech stocks are on an unaccustomed run. The SPDR S&P Biotech ETF, which trades under the ticker XBI, is up around 20% since the start of September, and is ...
Biotech stocks saw a major rebound in 2025, with key indexes significantly outperforming the S&P 500. Private investment in longevity science doubled in 2024, highlighting growing interest in ...
Denali Therapeutics Inc. (NASDAQ:DNLI) is one of the 10 best biotech stocks with highest upside potential. On April 6, Denali ...
The long winter for biotech stocks is over. Shares have climbed to levels not seen since late 2021, buoyed by eye-popping takeover valuations, trailblazing innovation in battling obesity and cancer, ...
The United States is at risk of losing one of the most important technology races of the 21st century: biotechnology. A 2025 report from a bipartisan, congressionally chartered commission warns that ...
Doubling survival in pancreatic cancer, a long-fought rare disease approval, a massive IPO and ambitious biotech ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results